Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Extensive-stage small-cell lung cancer, drawn from the whole corpus: 89 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No biomarker identifies the minority who gain long-term benefit from immunotherapy; PD-L1 and mutational burden do not work in small-cell disease.
Tarlatamab needs inpatient monitoring for cytokine release syndrome, which limits access outside specialist centres.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Whether the transcription factor subtypes can direct treatment is unproven.
Nothing recorded yet.
Nothing recorded yet.
Background: p53 / RB / cell-cycle checkpoint. Also on OnCo: Targets · KRAS roadmap.
Brain metastases remain common and prophylactic irradiation trades cognition for a benefit that is uncertain with MRI surveillance.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 36 changes by month →When this page itself was last checked or edited.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
European Commission approval for ES-SCLC